Vaccinex stock heads into November 16 earnings report
Published on 11/13/2026 at 00:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat investors are watching next
- Vaccinex is due to report its next results on Monday, November 16, 2026.
- Pepinemab remains the company's lead candidate across neurodegenerative disease and oncology research.
Vaccinex is scheduled to report its next results on Monday, November 16, 2026, according to Global Banking and Finance Review. The November 9 market analysis said the company was expected to release earnings the following Monday, putting the upcoming report at the center of the near-term investor calendar.
Results put pipeline in focus
The company is expected to update investors on its clinical-stage operations as it advances drug development in neurodegenerative disease and oncology. The report may also offer a fresh view of funding needs and the pace of development for its lead program.
Analysts listed by Global Banking and Finance Review expect earnings of negative 73.04 per share and revenue of 333,212 for the upcoming report. Those estimates are forward-looking and will be measured against the company's reported results.
Vaccinex's drug development strategy
Vaccinex is a biotechnology company developing antibody-based therapies for cancer and neurodegenerative diseases. Its lead candidate, pepinemab, blocks semaphorin 4D, a protein linked to neuroinflammation, immune suppression and tumor progression. The company is also using its ActivMAb platform to pursue additional drug-discovery opportunities and potential collaborations, as described in its investor overview.
Vaccinex at a glance
- Company: Vaccinex, Inc.
- Ticker: VCNX
- Sector: Health Care
- Next results: Monday, November 16, 2026
- Lead candidate: Pepinemab
In the wider US market, investors can follow the S&P 500 for the broader equity backdrop ahead of the report.
